Sign in Subscribe

CagriSema Falls Short vs Zepbound in Head-to-Head Trial

Novo’s new obesity shot CagriSema lost a head-to-head battle with Lilly’s tirzepatide. 23% weight loss is strong but not enough to win this round.

CagriSema Falls Short vs Zepbound in Head-to-Head Trial
Credit: Novo Nordisk
Already have an account? Sign in.